Choosing a Gliptin
The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up t...
Main Authors: | Vishal Gupta, Sanjay Kalra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2011-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=4;spage=298;epage=308;aulast=Gupta |
Similar Items
-
Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01) -
The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01) -
Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients
by: Olivier Gaudin, et al.
Published: (2018-05-01) -
Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus
by: Aleksandra Pilszyk, et al.
Published: (2022-09-01) -
Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)